A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Transgene
- 入组人数
- 148
- 试验地点
- 23
- 主要终点
- Progression free survival at 6 months
研究概览
简要总结
The primary Objective is to assess the efficacy of TG4010 combined to chemotherapy in comparison with chemotherapy alone in patients with advanced non small cell lung cancer.
详细描述
In the experimental arm patients receive subcutaneous injections of TG4010 at the dose of 108 pfu in combination with chemotherapy treatment whereas patients in the control arm receive chemotherapy alone. The chemotherapy associates cisplatin and gemcitabine and is given for up to 6 cycles or progressive disease, whichever occurs first.
TG4010 is administered once per week for 6 weeks, then once every 3 weeks in combination with chemotherapy and thereafter as monotherapy until documentation of progressive disease.
Tumor response will be evaluated every 6 weeks by a CT-scan and results will be available before starting an additional treatment period of 6 weeks. The tumor response taken into account will be for each patient the best overall response obtained during the study.
The endpoint of the study is based on Progression Free Survival (PFS) at 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed non-small cell carcinoma of the lung (adenocarcinoma, squamous cell carcinoma, or large cell carcinoma);
- •Histological documentation of MUC1 antigen expression on the primary tumor or on metastasis, as defined by a positive staining by immuno-histo-chemistry in at least 25% of the tumor cells in the conditions described in the technical documentation of the monoclonal antibody;
- •Patients will have stage IIIb "wet" (with pleural or pericardial effusion) or IV disease, with no prior systemic therapy for advanced disease except for adjuvant treatment. Prior surgery or radiation therapy aimed at local palliation or attempted local disease control is permitted;
- •At least one measurable lesion by Computed Tomography (CT-scanner) according to WHO criteria (lesion accurately measured in two dimensions with longest diameter equal or greater to 10 mm with spiral CT scan);
- •Adequate hematological, hepatic, and renal function:
- •Hemoglobin >= 10.0 g/dL; WBC >= 3.0x10e9/L including neutrophils >= 1.5x10e9/L and total lymphocytes count >= 0.5x10e9/L; platelets count >= 100x10e9/L;
- •Bilirubin =< 2x the upper limit of normal and serum transaminases =< 3x the upper limit of normal;
- •Glomerular Filtration Rate higher than 60 ml/mn according to Cockcroft formula;
- •Performance status 0 or 1 on the ECOG scale (Appendix 2);
- •Minimum estimated life expectancy of 4 months;
- •Written informed consent from patient.
排除标准
- •Concomitant brain metastases. If previous brain metastases were treated, the absence of evolution is to be demonstrated by the MRI or scanner performed at baseline;
- •Prior history of other malignancy except basal cell carcinoma and intra-epithelial cervical cancer or other cancer with complete response since at least 5 years;
- •History of any form of systemic therapy for advanced non-small cell cancer of the lung except for (neo)adjuvant treatment;
- •Previous (within 4 weeks prior to day 1) or concomitant long term treatment with systemic steroids, immunosuppressive / immunomodulating drugs (e.g. Cyclosporine, corticoïds);
- •Positive serology for HIV or HCV; positive antigens for hepatitis B;
- •Serious concomitant medical disorder;
- •Major surgery within 4 weeks prior to day 1;
- •Patient with an organ allograft;
- •Allergy to eggs;
- •Participation in another experimental protocol during the study period, or within 4 weeks prior to day 1;
- •Pregnancy at the entry or women who are breast feeding;
- •Patient without adequate protection against pregnancy during the conduct of the study and for 3 months after the last injection of TG4010 and/or chemotherapy;
- •History of substance abuse;
- •Patient unable or unwilling to comply with the protocol requirements.
研究组 & 干预措施
Arm 1
MVA-MUC1-IL2 in combination with 1st line Chemotherapy
干预措施: MVA-MUC1-IL2 (Biological)
Arm 1
MVA-MUC1-IL2 in combination with 1st line Chemotherapy
干预措施: 1st line Chemotherapy (Drug)
Arm 2
1st line Chemotherapy without a MVA-MUC1-IL2 combination
干预措施: 1st line Chemotherapy (Drug)
结局指标
主要结局
Progression free survival at 6 months
时间窗: 6 months
次要结局
- Quality of life(every 6 weeks)
- Response Rate according to WHO criteria(6 months)
- Time to progression(6 months)
- Overall survival